Although p300, BRD2, and G9a interact with the same Runt domain of RUNX3, these data suggest that cells undergo differential lysine modifications of RUNX3 through interactions with these proteins to adequately adapt them to the varying tumor microenvironment. Here, BRD2 is linked to neoplasm.